Research & Development

Denmark's First AI Supercomputer Gefion Launched to Propel Innovation
Research & Development Denmark's First AI Supercomputer Gefion Launched to Propel Innovation

In a landmark event for Denmark’s technology landscape, the nation's first AI supercomputer, Gefion, has been officially inaugurated. This momentous occasion promises to expedite drug discovery and address a variety of societal challenges. The Novo Nordisk Foundation, a principal player in the

Can This $2.1 Billion Deal Advance Breakthrough Treatments in Immunology?
Research & Development Can This $2.1 Billion Deal Advance Breakthrough Treatments in Immunology?

In a significant development, Monte Rosa Therapeutics, a biotechnology company based in Boston, has finalized a highly lucrative global exclusive development and commercialization license agreement with Novartis valued at up to $2.1 billion on October 28, 2024. Monte Rosa Therapeutics is focused on

How Will AI Transform Drug Discovery and Development in Biopharma?
Research & Development How Will AI Transform Drug Discovery and Development in Biopharma?

Artificial Intelligence (AI) has the potential to revolutionize drug discovery and development, offering numerous advantages that could transform current practices in the biopharmaceutical industry. By merging Accenture's advanced capabilities in AI scaling with the innovative ITO™ platform d

Ryvu and nCage Partner to Innovate Antibody-Drug Conjugate Therapies
Research & Development Ryvu and nCage Partner to Innovate Antibody-Drug Conjugate Therapies

In a pioneering move to advance cancer treatment, Ryvu Therapeutics and nCage Therapeutics have announced a research collaboration aimed at developing a next-generation antibody-drug conjugate (ADC) platform. This partnership promises to leverage nCage's TRAP cage platform, a novel drug

Biond and Merck KGaA Partner to Trial New Treatment for Solid Tumors
Research & Development Biond and Merck KGaA Partner to Trial New Treatment for Solid Tumors

Biond Biologics Ltd., a private biopharmaceutical company, has entered into a partnership with Merck KGaA, Darmstadt, Germany, to support a Phase 1 clinical trial aimed at treating patients with unresectable or metastatic solid tumors. This clinical trial, designated as BND-35-001 (NCT06274437),

How Does ROXYBOND Fight Opioid Abuse and Ensure Pain Relief?
Research & Development How Does ROXYBOND Fight Opioid Abuse and Ensure Pain Relief?

The recent FDA approval of Protega Pharmaceuticals Inc.'s ROXYBOND (oxycodone hydrochloride) immediate-release (IR) CII 10 mg tablet marks a significant milestone in managing severe pain where alternative treatments fall short. ROXYBOND 10 mg stands out as the first FDA-approved

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later